Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation - NCT05179057

Proportion of participants with undetectable viremia (less than lower limit of quantitation [LLOQ]) at Day 29, Incidence and severity of adverse events (AEs), including AE's of special interest (AESIs), Incidence and severity of acute GVHD during the study, (and 5 more...)